pyrimethamine has been researched along with Body Weight in 20 studies
Maloprim: contains above 2 cpds
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sulfadoxine-pyrimethamine with amodiaquine (SP-AQ) is a highly efficacious regimen for intermittent preventive treatment to prevent malaria in children (IPTc), but the amodiaquine component is not always well tolerated." | 9.14 | Amodiaquine dosage and tolerability for intermittent preventive treatment to prevent malaria in children. ( Ba, EH; Cairns, M; Cames, C; Cisse, B; Gaye, O; Greenwood, BM; Milligan, PJ; Simondon, K; Sokhna, C; Trape, JF, 2010) |
| "The population pharmacokinetics of pyrimethamine (PYR) and sulfadoxine (SDX) for a group of 32 children with congenital toxoplasmosis was investigated by nonparametric modeling analysis." | 9.11 | Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis. ( Al Kurdi, M; Charpiat, B; Chaulet, JF; Corvaisier, S; Leboucher, G; Mounier, C; Peyron, F; Wallon, M, 2004) |
| "Between 1993 and 1999, we monitored the efficacy of sulfadoxine-pyrimethamine in 1175 children aged <24 months receiving 2789 treatments for falciparum malaria in western Kenya using a widely deployed age-based dose regimen: infants, 125 plus 6." | 9.10 | Sulfadoxine-pyrimethamine in treatment of malaria in Western Kenya: increasing resistance and underdosing. ( Courval, JM; Hawley, WA; Kariuki, SK; Kolczak, MS; Kuile, FO; Lal, AA; Nahlen, BL; Oloo, AJ; Rosenberg, OS; Terlouw, DJ, 2003) |
| "This study retrospectively studied amendable determinants of sulfadoxine-pyrimethamine (SP) efficacy involving 2869 treatments among 1072 Kenyan children <5 years old who had uncomplicated malaria." | 7.72 | Treatment history and treatment dose are important determinants of sulfadoxine-pyrimethamine efficacy in children with uncomplicated malaria in Western Kenya. ( Courval, JM; Kager, PA; Kolczak, MS; Lal, AA; Nahlen, BL; Oloo, AJ; Rosenberg, OS; ter Kuile, FO; Terlouw, DJ, 2003) |
| "The authors describe a two-year investigation carried out on a group of Nigerian schoolchildren with the object of assessing the effect of suppressing malaria infection with pyrimethamine on the physical development of the African child." | 7.63 | Suppression of malaria with pyrimethamine in Nigerian schoolchildren. ( ARCHIBALD, HM; BRUCE-CHWATT, LJ, 1956) |
| "Sulfadoxine-pyrimethamine with amodiaquine (SP-AQ) is a highly efficacious regimen for intermittent preventive treatment to prevent malaria in children (IPTc), but the amodiaquine component is not always well tolerated." | 5.14 | Amodiaquine dosage and tolerability for intermittent preventive treatment to prevent malaria in children. ( Ba, EH; Cairns, M; Cames, C; Cisse, B; Gaye, O; Greenwood, BM; Milligan, PJ; Simondon, K; Sokhna, C; Trape, JF, 2010) |
| "The population pharmacokinetics of pyrimethamine (PYR) and sulfadoxine (SDX) for a group of 32 children with congenital toxoplasmosis was investigated by nonparametric modeling analysis." | 5.11 | Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis. ( Al Kurdi, M; Charpiat, B; Chaulet, JF; Corvaisier, S; Leboucher, G; Mounier, C; Peyron, F; Wallon, M, 2004) |
| "Between 1993 and 1999, we monitored the efficacy of sulfadoxine-pyrimethamine in 1175 children aged <24 months receiving 2789 treatments for falciparum malaria in western Kenya using a widely deployed age-based dose regimen: infants, 125 plus 6." | 5.10 | Sulfadoxine-pyrimethamine in treatment of malaria in Western Kenya: increasing resistance and underdosing. ( Courval, JM; Hawley, WA; Kariuki, SK; Kolczak, MS; Kuile, FO; Lal, AA; Nahlen, BL; Oloo, AJ; Rosenberg, OS; Terlouw, DJ, 2003) |
| " Since prophylaxis with amodiaquine at 5 mg/kg weekly had failed, amodiaquine at a dose of 10mg/kg weekly and Maloprim (half a tablet or one tablet depending on body weight, which gave ranges of dapsone of 1." | 5.07 | Chemoprophylaxis against malaria in Papua New Guinea: a trial of amodiaquine and a combination of dapsone and pyrimethamine. ( Alpers, MP; Gibney, S; Gibson, FD; Heywood, PF; Jolley, D; Stace, J; Trenholme, KR; Vrbova, H, 1992) |
| "Less than a year after the introduction of amodiaquine (AQ)/sulfadoxine-pyrimethamine (SP) as the first-line antimalarial treatment in Senegal, our study aimed to assess patients' drug intake and check its correspondence with nurses' prescription-adherence, the national guidelines regimen and theoretical dosage." | 3.76 | Child age or weight: difficulties related to the prescription of the right dosage of antimalarial combinations to treat children in Senegal. ( Lalou, R; Le Hesran, JY; Senghor, P; Souares, A, 2010) |
| "This study retrospectively studied amendable determinants of sulfadoxine-pyrimethamine (SP) efficacy involving 2869 treatments among 1072 Kenyan children <5 years old who had uncomplicated malaria." | 3.72 | Treatment history and treatment dose are important determinants of sulfadoxine-pyrimethamine efficacy in children with uncomplicated malaria in Western Kenya. ( Courval, JM; Kager, PA; Kolczak, MS; Lal, AA; Nahlen, BL; Oloo, AJ; Rosenberg, OS; ter Kuile, FO; Terlouw, DJ, 2003) |
| "The authors describe a two-year investigation carried out on a group of Nigerian schoolchildren with the object of assessing the effect of suppressing malaria infection with pyrimethamine on the physical development of the African child." | 3.63 | Suppression of malaria with pyrimethamine in Nigerian schoolchildren. ( ARCHIBALD, HM; BRUCE-CHWATT, LJ, 1956) |
| " Suboptimal dosing in children may lead to treatment failure and increased resistance." | 1.48 | Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria. ( Allen, EN; Barnes, KI; Bell, DJ; de Kock, M; Denti, P; Djimde, AA; Tarning, J; Tekete, MM; Ward, SA; Workman, L, 2018) |
| "This work shows that an early treatment of a malaria infection produced by a non-lethal parasite drives the immune response towards a loss of cross-protection to further infections, in particular with more virulent parasites." | 1.32 | Early treatment during a primary malaria infection modifies the development of cross immunity. ( Hernández-Clemente, FF; Legorreta-Herrera, M; Licona-Chávez, RN; Soto-Cruz, I; Ventura-Ayala, ML, 2004) |
| " From the results obtained, it is concluded that 2-weeks repeated dosing with PYR is sufficient to detect toxicity on male reproductive organs in rats using histopathological examination." | 1.31 | Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 21). Comparison of the effects of 2- and 4-weeks pyrimethamine treatment in rats. ( Fujii, H; Masuda, T; Murakami, Y; Ogasawara, H; Suzuki, Y; Takeda, M, 2000) |
| "Amprolium was effective against E." | 1.27 | Effectiveness of therapeutic anticoccidial drugs against recently isolated coccidia. ( Mathis, GF; McDougald, LR; McMurray, B, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (30.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vrbova, H | 1 |
| Gibney, S | 1 |
| Gibson, FD | 1 |
| Jolley, D | 1 |
| Heywood, PF | 1 |
| Stace, J | 1 |
| Trenholme, KR | 1 |
| Alpers, MP | 1 |
| de Kock, M | 1 |
| Tarning, J | 1 |
| Workman, L | 1 |
| Allen, EN | 1 |
| Tekete, MM | 1 |
| Djimde, AA | 1 |
| Bell, DJ | 1 |
| Ward, SA | 1 |
| Barnes, KI | 1 |
| Denti, P | 1 |
| Souares, A | 1 |
| Lalou, R | 1 |
| Senghor, P | 1 |
| Le Hesran, JY | 1 |
| Cairns, M | 1 |
| Cisse, B | 1 |
| Sokhna, C | 1 |
| Cames, C | 1 |
| Simondon, K | 1 |
| Ba, EH | 1 |
| Trape, JF | 1 |
| Gaye, O | 1 |
| Greenwood, BM | 2 |
| Milligan, PJ | 3 |
| Konaté, AT | 1 |
| Yaro, JB | 1 |
| Ouédraogo, AZ | 1 |
| Diarra, A | 1 |
| Gansané, A | 1 |
| Soulama, I | 1 |
| Kangoyé, DT | 1 |
| Kaboré, Y | 1 |
| Ouédraogo, E | 1 |
| Ouédraogo, A | 1 |
| Tiono, AB | 1 |
| Ouédraogo, IN | 1 |
| Chandramohan, D | 2 |
| Cousens, S | 2 |
| Sirima, SB | 1 |
| Diallo, DA | 2 |
| Dicko, A | 1 |
| Barry, A | 1 |
| Dicko, M | 1 |
| Diallo, AI | 1 |
| Tembine, I | 1 |
| Dicko, Y | 1 |
| Dara, N | 1 |
| Sidibe, Y | 1 |
| Santara, G | 1 |
| Conaré, T | 1 |
| Doumbo, OK | 1 |
| Greenwood, B | 1 |
| Terlouw, DJ | 2 |
| Courval, JM | 2 |
| Kolczak, MS | 2 |
| Rosenberg, OS | 2 |
| Oloo, AJ | 2 |
| Kager, PA | 1 |
| Lal, AA | 2 |
| Nahlen, BL | 2 |
| ter Kuile, FO | 1 |
| Kariuki, SK | 1 |
| Hawley, WA | 1 |
| Kuile, FO | 1 |
| ARCHIBALD, HM | 1 |
| BRUCE-CHWATT, LJ | 1 |
| BALL, SJ | 1 |
| Legorreta-Herrera, M | 1 |
| Ventura-Ayala, ML | 1 |
| Licona-Chávez, RN | 1 |
| Soto-Cruz, I | 1 |
| Hernández-Clemente, FF | 1 |
| Corvaisier, S | 1 |
| Charpiat, B | 1 |
| Mounier, C | 1 |
| Wallon, M | 1 |
| Leboucher, G | 1 |
| Al Kurdi, M | 1 |
| Chaulet, JF | 1 |
| Peyron, F | 1 |
| Pitmang, SL | 1 |
| Thacher, TD | 1 |
| Madaki, JK | 1 |
| Egah, DZ | 1 |
| Fischer, PR | 1 |
| Shao, BR | 1 |
| Zhan, CQ | 1 |
| Ha, SH | 1 |
| Ni, YC | 1 |
| Mathis, GF | 1 |
| McDougald, LR | 1 |
| McMurray, B | 1 |
| Kalla, NR | 1 |
| Saggar, SK | 1 |
| Puri, R | 1 |
| Mehta, U | 1 |
| Macintire, DK | 1 |
| Vincent-Johnson, NA | 1 |
| Kane, CW | 1 |
| Lindsay, DS | 1 |
| Blagburn, BL | 1 |
| Dillon, AR | 1 |
| Murakami, Y | 1 |
| Takeda, M | 1 |
| Suzuki, Y | 1 |
| Fujii, H | 1 |
| Ogasawara, H | 1 |
| Masuda, T | 1 |
| Castles, TR | 1 |
| Kintner, LD | 1 |
| Lee, CC | 1 |
| Jackson, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Single-course Malaria Chemoprevention on Clearance of and Protection From Plasmodium Falciparum Infection in the Presence of Resistance-associated Genotypes in Cameroon[NCT06173206] | Phase 3 | 900 participants (Anticipated) | Interventional | 2024-03-15 | Not yet recruiting | ||
| A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children[NCT00738946] | 6,000 participants (Anticipated) | Interventional | 2008-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 trials available for pyrimethamine and Body Weight
| Article | Year |
|---|---|
Chemoprophylaxis against malaria in Papua New Guinea: a trial of amodiaquine and a combination of dapsone and pyrimethamine.
Topics: Antimalarials; Body Weight; Child; Child, Preschool; Dapsone; Drug Combinations; Drug Resistance; Fe | 1992 |
Amodiaquine dosage and tolerability for intermittent preventive treatment to prevent malaria in children.
Topics: Age Factors; Amodiaquine; Antimalarials; Body Weight; Child; Child, Preschool; Dose-Response Relatio | 2010 |
Morbidity from malaria in children in the year after they had received intermittent preventive treatment of malaria: a randomised trial.
Topics: Amodiaquine; Anemia; Antimalarials; Body Weight; Burkina Faso; Child, Preschool; Double-Blind Method | 2011 |
Malaria morbidity in children in the year after they had received intermittent preventive treatment of malaria in Mali: a randomized control trial.
Topics: Amodiaquine; Anemia; Antimalarials; Body Weight; Child, Preschool; Drug Administration Schedule; Dru | 2011 |
Sulfadoxine-pyrimethamine in treatment of malaria in Western Kenya: increasing resistance and underdosing.
Topics: Anti-Infective Agents; Antimalarials; Body Weight; Drug Combinations; Drug Resistance; Female; Human | 2003 |
Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis.
Topics: Antiprotozoal Agents; Bayes Theorem; Body Weight; Child; Chromatography, High Pressure Liquid; Follo | 2004 |
Comparison of sulfadoxine-pyrimethamine with and without chloroquine for uncomplicated malaria in Nigeria.
Topics: Adolescent; Adult; Antimalarials; Body Weight; Child; Chloroquine; Drug Therapy, Combination; Female | 2005 |
13 other studies available for pyrimethamine and Body Weight
| Article | Year |
|---|---|
Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria.
Topics: Africa; Age Factors; Amodiaquine; Antimalarials; Biomarkers, Pharmacological; Body Weight; Chemoprev | 2018 |
Child age or weight: difficulties related to the prescription of the right dosage of antimalarial combinations to treat children in Senegal.
Topics: Adolescent; Adult; Age Factors; Antimalarials; Body Weight; Child; Child, Preschool; Drug Combinatio | 2010 |
Treatment history and treatment dose are important determinants of sulfadoxine-pyrimethamine efficacy in children with uncomplicated malaria in Western Kenya.
Topics: Age Factors; Animals; Antimalarials; Body Weight; Child, Preschool; Dose-Response Relationship, Drug | 2003 |
Suppression of malaria with pyrimethamine in Nigerian schoolchildren.
Topics: Antimalarials; Body Weight; Child; Drug Combinations; Humans; Malaria; Malaria, Falciparum; Pyrimeth | 1956 |
SYNERGISTIC ACTION OF SULPHAQUINOXALINE AND 2-AMINO-4-DIMETHYLAMINO-5-(4-CHLOROPHENYL)-6-ETHYLPYRIMIDINE IN CAECAL COCCIDIOSIS IN CHICKENS.
Topics: Animals; Blood; Body Weight; Cecum; Chickens; Coccidiosis; Intestinal Diseases; Intestinal Diseases, | 1964 |
Early treatment during a primary malaria infection modifies the development of cross immunity.
Topics: Animals; Antibodies, Protozoan; Body Weight; Cross Reactions; Gene Expression; Hemoglobins; Immunity | 2004 |
[Embryotoxicity of chloroquine and pyrimethamine in rats].
Topics: Abnormalities, Drug-Induced; Animals; Body Weight; Bone and Bones; Chloroquine; Embryo, Mammalian; F | 1983 |
Effectiveness of therapeutic anticoccidial drugs against recently isolated coccidia.
Topics: Amprolium; Animals; Body Weight; Chickens; Coccidiosis; Coccidiostats; Drug Combinations; Drug Resis | 1984 |
Regulation of male fertility by pyrimethamine in adult mice.
Topics: Animals; Body Weight; Cell Cycle; Contraceptive Agents, Male; Female; Fertility; Folic Acid Antagoni | 1997 |
Treatment of dogs infected with Hepatozoon americanum: 53 cases (1989-1998).
Topics: Alkaline Phosphatase; Animals; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Antiprotozoal | 2001 |
Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 21). Comparison of the effects of 2- and 4-weeks pyrimethamine treatment in rats.
Topics: Administration, Oral; Animals; Antimalarials; Body Weight; Dose-Response Relationship, Drug; Epididy | 2000 |
The effects of folic or folinic acid on the toxicity of pyrimethamine in dogs.
Topics: Animals; Blood Chemical Analysis; Body Weight; Dogs; Drug Combinations; Female; Folic Acid; Hemodyna | 1971 |
A comparison of the toxicity of the coccidiostats diaveridine and pyrimethamine in the chick and the effect of an antibiotic on the anti-folic activity of pyrimethamine.
Topics: Adrenal Glands; Animal Feed; Animals; Antifungal Agents; Bacitracin; Body Weight; Coccidioides; Estr | 1966 |